HAVAH Therapeutics
More than 25 years in biotechnology including 9 years in patent attorney practice. Leadership roles in biotech companies have included CEO of ASX listed Dimerix Ltd and current Director of Disruptive Nutrition Pty Ltd. Kathy has extensive experience in intellectual property strategy, commercial drug development strategy and achieving drug development milestones. Kathy’s qualifications in science, intellectual property law and governance provide the depth of skill to lead HAVAH through its next stage of growth.
This person is not in any offices
HAVAH Therapeutics
HAVAH Therapeutics is focused on developing better hormonal therapies to help millions of women lead longer, better lives.